Stay updated with breaking news from Jamese Bradner. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS – Get Rating) has received a consensus recommendation of “Moderate Buy” from the five brokerages that are covering the company, MarketBeat reports. One research analyst has rated the stock with a hold rating and three have issued a buy rating on the company. The average 1-year target price among brokerages that […]
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS – Get Rating) was the recipient of a significant increase in short interest in March. As of March 15th, there was short interest totalling 649,500 shares, an increase of 21.6% from the February 28th total of 534,300 shares. Based on an average trading volume of 131,800 shares, the days-to-cover ratio is […]
Should You Buy or Sell Syros Pharmaceuticals Stock? Get The Latest SYRS Stock Forecast, Price Target, Earnings Estimates, Headlines, Short Interest at MarketBeat.
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS – Get Rating) has earned an average recommendation of “Moderate Buy” from the six analysts that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1 year target price among […]
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS – Get Rating) has received an average recommendation of “Moderate Buy” from the six research firms that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average twelve-month price objective among […]